IRONWOOD PHARMACEUTICALS INC (IRWD) SEC Filings

IRONWOOD PHARMACEUTICALS INC (symbol: IRWD) is the issuer of record for a Form 4 filing submitted to the SEC. DENNER ALEXANDER J reported acquisition or exercise transactions in this Form 4 filing.

IRONWOOD PHARMACEUTICALS INC (IRWD) reported that director Alexander J. Denner received an equity grant of 3,694 shares of Class A Common Stock on September 15, 2026. The shares were issued at no cash cost under the company’s Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, increasing his direct holdings to 327,549 shares. No Rule 10b5-1 trading plan is reported for this award.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of Class A common stock of Ironwood Pharmaceuticals, Inc. Amendment No. 7 states that they may be deemed to beneficially own 13,932,000 shares, representing 8.43% of the outstanding class as of June 30, 2026.

All 13,932,000 shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager with shared voting and dispositive power and no sole power. Steven Boyd, as managing member of Armistice Capital, may also be deemed a beneficial owner. The Master Fund has the right to receive dividends and sale proceeds on these securities.

State Street Corporation reported beneficial ownership of Ironwood Pharmaceuticals common stock on a passive Schedule 13G. State Street and its investment management subsidiaries reported beneficial ownership of 8,809,601 shares of common stock, representing 5.4% of the outstanding class.

The filing states 0 shares with sole voting or dispositive power and 8,588,456 shares with shared voting power, and 8,809,601 shares with shared dispositive power. The shares are held through entities including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company.

Ironwood Pharmaceuticals, Inc. reported total revenues of $113,041 thousand for the quarter ended June 30, 2026, up from $85,239 thousand a year earlier, driven almost entirely by collaborative arrangements revenue. Net income rose to $51,291 thousand from $23,599 thousand. For the first six months of 2026, revenues were $219,547 thousand and net income was $92,064 thousand, compared with revenues of $126,382 thousand and a net loss of $13,787 thousand in 2025.

Cash and cash equivalents were $79,127 thousand at June 30, 2026. Net cash provided by operating activities increased to $63,397 thousand for the six-month period. Ironwood repaid $200,000 thousand of 1.50% convertible senior notes at maturity in June 2026 and had $385,000 thousand outstanding under its revolving credit facility. Total liabilities were $446,971 thousand and stockholders’ deficit narrowed to $161,843 thousand.

The company continues to commercialize LINZESS globally through partners including AbbVie, Astellas and Grand Life Sciences and to earn royalties on CONSTELLA. It is advancing apraglutide for short bowel syndrome with intestinal failure, having initiated the STARS-2 confirmatory Phase III trial in June 2026 while continuing the STARS Extend open-label study.

Ironwood Pharmaceuticals reported strong Q2 2026 results and raised its full‑year 2026 financial guidance. Total revenue was $113 million compared with $85 million in Q2 2025, driven largely by LINZESS® performance. GAAP net income was $51 million, or $0.31 per diluted share, versus $23.6 million, or $0.14, a year earlier. Adjusted EBITDA was $83 million, up from $50.1 million in Q2 2025.

LINZESS U.S. net sales were $282 million in the quarter and $555 million year‑to‑date, representing 44% year‑over‑year growth. Reflecting this, 2026 LINZESS U.S. net sales guidance increased to $1.15–$1.20 billion (greater than 30% growth year‑over‑year), total revenue guidance to $460–$485 million, and adjusted EBITDA guidance to more than $310 million. Ironwood also repaid $200 million of convertible notes using cash on hand, and initiated the confirmatory Phase 3 STARS‑2 trial of apraglutide in short bowel syndrome with intestinal failure, which is now actively recruiting patients.

BlackRock, Inc. reports beneficial ownership of Class A stock of Ironwood Pharmaceuticals Inc on an amended Schedule 13G (Amendment No. 6). BlackRock and certain of its business units collectively beneficially own 13,373,568 shares, representing 8.1% of Ironwood’s outstanding Class A stock.

BlackRock has sole voting power over 13,195,313 shares and sole dispositive power over all 13,373,568 shares, with no shared voting or dispositive power reported. Various underlying clients and accounts have rights to dividends or sale proceeds, but no single person’s interest exceeds five percent of Ironwood’s outstanding common shares.

Silber Jeffrey reported acquisition or exercise transactions in this Form 4 filing.

Ironwood Pharmaceuticals Inc granted its SVP, CMO and Head of Research & Drug Development, Jeffrey Silber, a new-hire restricted stock unit award covering 137,036 shares of Class A Common Stock. The award vests 25% of the shares on each approximate anniversary of the grant, resulting in direct ownership of 137,036 shares.

IRONWOOD PHARMACEUTICALS INC filed an initial insider ownership report identifying Jeffrey Silber, its SVP, CMO and Head-Res&Drug, as the reporting person. The filing notes Exhibit 24, a Power of Attorney, and shows no insider share transactions in this record.

Ironwood Pharmaceuticals’ principal financial and accounting officer Ronald Silver sold 127,890 shares of Class A common stock in an open-market transaction. The sale was executed under a pre-arranged Rule 10b5-1 trading plan at a weighted average price of $4.52 per share, with individual trade prices ranging from $4.50 to $4.57.

After this transaction, Silver directly holds 313,680 Ironwood shares, indicating he retains a significant equity stake even after the planned sale.